Volociximab

From Self-sufficiency
Jump to: navigation, search
Volociximab
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target α5β1 integrin
Identifiers
CAS Number 558480-40-3
ATC code none
Chemical data
Formula C6434H9942N1706O2040S52
Molar mass 145.5 kDa[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.[1]

It is thought to reduce metastases. Early results show potential in renal cell cancers. [ref needed]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links


  1. Ng, CM; Bai, S; Takimoto, CH; Tang, MT; Tolcher, AW (2009). "Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha(5)beta (1) integrin monoclonal antibody (volociximab) in cancer patients". Cancer chemotherapy and pharmacology. 65: 207. doi:10.1007/s00280-009-1023-8. PMID 19468731.